24 publications
Name | Date | Type | Actions |
---|---|---|---|
Q3 2020 sales: €114.5 million* (Up 14.3%) Vetoquinol posted sales of €114.5 million for the third quarter of 2020, up 14.3% as reported compared to the same period last year. |
15/10/2020 | Public releases | |
VETOQUINOL, SNGTV and FARMVETSYSTEMS sign a partnership agreement to offer a common, innovative digital solution to the veterinary healthcare market. September 28th, 2020 (Paris, France) VETOQUINOL, FARMVET SYSTEMS and SNGTV have signed a partnership agreement aimed at offering a common solution highlighting the complementarity of their two software, VetIMPRESS and Vetélevage to farm vets. Aware of their shared philosophy aimed at optimizing vets actions thanks to new digital technologies, they are pooling these two software programs to strengthen the role of farm vets in animal health and welfare. |
28/09/2020 | Public releases | |
Vetimpress delivering digital solutions to farm vets with a growing network of partnerships September 21st, 2020 (Northern Ireland) – VetIMPRESS the secure data management platform has recently implemented a series of integrations, reinforcing its position as a leading source of information for farm animal vets. The platform has grown its connections to over 100 external sources across 10 countries. The partnerships are set to improve connectivity across the industry, providing a single source of truth to better inform ethical, safe and productive veterinary decisions. |
21/09/2020 | Public releases | |
Vetoquinol finalizes the acquisition of Profender® and Drontal® product families September 1st, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1st, 2020. |
02/09/2020 | Public releases | |
2020 first half results consolidated sales: €196.1m (up 7.5% at constant exchange rates) net income group share: €15.1m (7.7% of sales) At its meeting on July 29, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the first half 2020 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
30/07/2020 | Public releases | |
Vetoquinol is moving forward with the acquisition of Profender® and Drontal® and related pipeline assets following communication from the European commission June 9th, 2020 (Lure, France) - The European Commission (EC) has approved, under the EU merger Regulation, the proposed acquisition of Bayer’s Animal Health Division by Elanco Animal Health. |
09/06/2020 | Public releases | |
Dominique Derveaux appointed Group Chief Operations Officer
Effective April 1, 2020, Vetoquinol’s Board of Directors has appointed Dominique Derveaux Group Chief Operations Officer. In this capacity, he will run the Business, Marketing & Medical, Industrial, and Information Systems departments. He will report to Vetoquinol CEO Matthieu Frechin. |
28/04/2020 | Public releases | |
Availability of the 2019 universal registration document Vetoquinol informs that it has filed its 2019 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on April 23, 2020. |
23/04/2020 | Public releases | |
Q1 2020 sales €103.4 million (Up 13.7%) Vetoquinol Group sales for Q1 2020 amounted to €103.4 million, up 13.7% as reported and up 13.4% at constant exchange rates. |
16/04/2020 | Public releases | |
2019 annual results: group sales €396.0M, up 6.1% at constant exchange rates. Net income group share: €28.6M (7.2% of sales) At its meeting on March 24, 2020, the Vetoquinol S.A. Board of Directors reviewed the Group results and approved the 2019 financial statements. The auditors have completed their audit of the financial statements and will shortly issue their report thereon. |
26/03/2020 | Public releases | |
Covid-19: Vetoquinol donates masks to neighboring healthcare facilities Vetoquinol S.A, the animal health laboratory based in Lure (70) has decided to donate more than 6000 masks to hospitals and associations in the region. This is a civic action to help, amongst others, hospitals in the Belfort Montbéliard, Vesoul and Saint-Rémy regions. |
20/03/2020 | Public releases | |
Vetoquinol to acquire rights for Profender® and Drontal® from Elanco Animal Health for the European economic area and the UK February 12 th , 2020 (Lure, France) - Vetoquinol has agreed terms to acquire the European Economic area and UK rights to Profender® and Drontal® product families from Elanco Animal Health. |
12/02/2020 | Public releases | |
2019 sales: €396.0 million (Up 7.6%) The Vetoquinol Group posted 2019 sales of €396.0 million, up 7.6% as reported and up 6.1% at constant exchange rates. |
23/01/2020 | Public releases | |
Vetoquinol et nippon Zenyaku Kogyo Co. ltd. signent un accord de joint-venture au Japon Vetoquinol and Nippon Zenyaku Kogyo Co., Ltd., also operating under the trade name “Zenoaq”, announced today the signature of a joint-venture agreement to develop, register and market a range of animal health products in Japan. |
03/12/2015 | Public releases | |
September 2015 year-to-date sales up 8.7% to €251.8 million Vetoquinol sales for the first nine months of 2015 rose 8.7% to €251.8 million, boosted by a positive currency impact of €13.7 million. Organic growth for the same period came to 0.7%. |
22/10/2015 | Public releases | |
VETOQUINOL launches UPCARD©, an innovative drug for congestive heart failure in dogs Vétoquinol continues the deployment of its reference products with the European launch of UPCARD©, an innovative drug designed to treat congestive heart failure in dogs. |
14/09/2015 | Public releases | |
First half 2015 sales €167.2m, up 11.9% The July 29, 2015 Vétoquinol SA Board of Directors meeting reviewed Group revenues and approved the H1 2015 financial statements. |
30/07/2015 | Public releases | |
Communiqué de mise à disposition du rapport financier semestriel relatif à l’exercice 2015 (french) Le rapport financier semestriel relatif à l’exercice 2015 peut être consulté ou téléchargé sur les sites |
30/07/2015 | Public releases | |
Vétoquinol is eligible for new PEA-PME funds Vétoquinol confirms that it qualifies for the PEA-PME investment product in accordance with Decree |
23/05/2015 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2015 (french version) The registration document of Vétoquinol relative to fiscal year 2014, including the annual financial report relative to fiscal year 2014, was filed with the Autorité des marchés financiers (“the AMF”) on April 17, 2015. |
20/04/2015 | Public releases | |
Q1 2015 sales show solid growth at €81.3 million (up +11.0%) Vétoquinol posted first quarter 2015 sales of €81.3 million (after currency gains of €4.5 million), up +11.0%. At constant exchange rates, first quarter 2015 sales amounted to €76.7 million, a +4.8% increase from €73.2 million in Q1 2014. |
14/04/2015 | Public releases | |
Reference products up +13.2%. net income up +9.3% Lure, March 23, 2015 – At its meeting on March 17, 2015, the Vétoquinol S.A. Board of Directors reviewed the Group results and approved the 2014 financial statements. |
23/03/2015 | Public releases | |
Vétoquinol and Orion Pharma Animal Health enter into distribution collaboration Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products. |
05/02/2015 | Public releases | |
2014 sales up 5.2% to €315.3 million The Vétoquinol Group posted 2014 sales of €315.3 million, up 5.2% from the previous year. At constant exchange rates, sales rose by 6.3%. The Vétoquinol Group achieved organic growth of 1.4% in 2014. |
22/01/2015 | Public releases |